Mangoceuticals shares results from field studies on MGX-0024

Mangoceuticals (MGRX) shares results from field studies based on its patented antiviral compound which it refers to as “MGX-0024”. The field studies were conducted by Solice International at Duraiswamy Farm in Palladam, Tamil Nadu, India. These studies, targeting respiratory diseases in chickens, like Newcastle Disease and Chronic Respiratory Disease, CRD, showed MGX-0024, delivered through drinking water, achieved 100% survival against respiratory illnesses in a large-scale trial, offering a promising solution for poultry health and avian flu defense. In the first study, 8,000 chickens starting at 25 days old received MGX-0024-infused water, resulting in about 50 deaths per day from respiratory diseases, compared to 200 per day on a neighboring untreated farm using the same chick batch. The farm noted that some deaths may have been due to pre-infected chickens too weak to drink the treated water. In a second study, 10,000 chicks treated from 7 days old, for 48 days, with no other antibacterial or antiviral feed additives administered, had no deaths from respiratory diseases, despite an expected 50% mortality rate based on a nearby farm’s losses. Only 20 chickens died due to unrelated heat exposure. MGX-0024, a blend of natural polyphenols and zinc, Generally Recognized as Safe ingredients, is also under evaluation for use in preventing avian flu in a lab study with Vipragen Biosciences and an Indian government laboratory, with results expected soon.